Earnings Call Summary | Zynex(ZYXI.US) Q1 2024 Earnings Conference
Earnings Call Summary | Zynex(ZYXI.US) Q1 2024 Earnings Conference
The following is a summary of the Zynex, Inc. (ZYXI) Q1 2024 Earnings Call Transcript:
以下是Zynex, Inc.（ZYXI）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Zynex reported a 10% increase in Q1 2024 revenue year-over-year, despite slight disruptions caused by a cyber event.
An estimated revenue of $1 million, delayed due to the cyber event, is expected to be recognized throughout 2024.
The company reconfirmed its 2024 guidance of at least $227 million.
Positive cash flow from operations in Q1 2024 was $2.1 million.
Zynex報告稱，儘管網絡事件造成了輕微的干擾，但2024年第一季度的收入同比增長了10％。
由於網絡事件而推遲的估計收入爲100萬美元，預計將在2024年全年得到確認。
該公司重申了其2024年至少2.27億美元的預期。
2024 年第一季度運營產生的正現金流爲 210 萬美元。
Business Progress:
業務進展：
The company's sales team is consistently expanding, supporting the growth in earnings and revenue.
FDA clearance has been received for the M-Wave Neuromuscular Electrical Stimulation device which has begun shipping to patients.
Significant advancements have been seen in the monitoring division, specifically in the blood and fluid monitor technologies.
FDA clearance was achieved for the second generation blood and fluid monitor in the previous year.
Several products are in the pipeline, including a laser-based pulse oximeter, a sepsis detection monitor, and a total hemoglobin level monitor.
Additional regulatory milestones are expected in 2024.
Zynex is transitioning new prescriptions from the older E-Wave model to their M-Wave product.
NexWave products now comprise around 27%-28% of orders.
In 2025, the company plans to commercialize the NICO product.
Zynex is considering the option of going private.
Approximately $15 million remains from a previously announced $20 million share buyback plan.
該公司的銷售團隊不斷擴大，爲收益和收入的增長提供了支持。
M-Wave神經肌肉電刺激設備已獲得美國食品藥品管理局的批准，該設備已開始向患者發貨。
監測部門已經取得了重大進展，特別是在血液和液體監測技術方面。
去年，第二代血液和液體監測器獲得了美國食品藥品管理局的批准。
幾種產品正在研發中，包括基於激光的脈搏血氧計、敗血症檢測監視器和總血紅蛋白水平監測器。
預計2024年還會有更多監管里程碑。
Zynex正在將新處方從舊的E-Wave型號過渡到其M-Wave產品。
NexWave產品現在約佔訂單的27％-28％。
2025年，該公司計劃將NICO產品商業化。
Zynex正在考慮私有化的選擇。
此前宣佈的2000萬美元股票回購計劃還剩約1500萬美元。
More details: Zynex IR
更多詳情： Zynex IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。